High-cost Gilead cell therapy proves durable for some lymphoma patients

SAN DIEGO (Reuters) – Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc’s Yescarta were still responding to the cell therapy after at least two years of follow-up, the company said on Sunday. FILE PHOTO: A Gilead Sciences, Inc. office is shown in Foster City, California, U.S. May 1,… Read More »

5-Star Friday: Assumptions

Many of the medical truths we hold to be self-evident are actually assumptions. Our 5-Star selections this week are good examples. Many of us assume medical devices are rigorously tested before going to market. That bed rest keeps premature labor at bay. Or, that electronic medical records (EMRs) will make health care delivery more streamlined… Read More »

The Autistic Week That Was

— First things first. I can see how many of you off the spectrum, those referred to as neurotypicals, could read the headline as saying that people off the spectrum don’t understand people on the spectrum.That’s NOT what I’m saying at all. I’m saying it’s true that many on the spectrum aren’t understood by those… Read More »